Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease

Inclusion Criteria: * Men or women ≥ 18 years of age * Diagnosis of definite oGVHD using the International Chronic Ocular GVHD Consensus Group Revised Diagnostic criteria in at least one eye. * Ocular Discomfort score ≥ 3 * Validated Bulbar Redness score ≥ 40 in both eyes * Subjects who are capable and willing to provide informed consent and follow study instructions * Intraocular pressure (IOP) ≥ 5 mmHg and ≤22 mmHg in each eye * Women who are not pregnant or lactating or post-menopausal or have undergone a sterilization procedure Exclusion Criteria: * Allergic to brimonidine or any similar products, or excipients of brimonidine * Currently receiving any brimonidine or other treatment for glaucoma * Receiving or have received any investigational drug or device within 30 days of screening * Current use of contact lenses 14 days prior to screening * Active ocular infection or ocular allergies * Any history of eyelid surgery or ocular surgery within the past 3 months * Corneal epithelial defect larger than 1 mm (squared) in either eye * Received corticosteroid-containing eye drops within 14 days prior to screening or planned use during the study * Any change in corticosteroid-containing eye drops, systemic corticosteroids/immunosuppressives, topical ocular antibiotics, cyclosporine ophthalmic emulsion 0.05% (Restasis®), cyclosporine ophthalmic solution 0.09% (Cequa®) or lifitegrast ophthalmic solution 5% (Xiidra®), or autologous serum tears within 30 days prior to screening or planned change during the study